tbuckley/cabot-search huggingface dataset:
Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials
Authors: M. Elmeliegy, Y. Yu, J.K. Litton, N.C. Turner, A. Czibere, G.G. Wilson, I.C. Tudor, J. Zheng, D.D. Wang
Journal: Annals of Oncology (2018)
Abstract 18427: Low Left Ventricular Ejection Fraction and β-blocker Use Before Admission is Associated With In-hospital Cardiac Complications in Patients With Takotsubo Cardiomyopathy
Authors: Ken Kato, Yuichi Saito, Yoshiaki Sakai, Iwao Ishibashi, Masashi Yamamoto, Toshiharu Himi, Yoshihide Fujimoto, Yoshio Kobayashi
Journal: Circulation (2015)

Introduction: The prognosis of patients with takotsubo cardiomyopathy (TC) is thought to be relatively favorable. However, serious cardiac complications during hospitalization occur in some patients. There is little information about risk factors associated with in-hospital cardiac complications in patients with TC. Hypothesis: We assessed the hypothesis that severe left ventricular (LV) dysfunction is associated with in-hospital cardiac complications in patients with TC. Methods: A total of 154 consecutive patients with TC based on Mayo criteria were enrolled. Coronary angiography and left ventriculography were performed in all patients and absence of obstructive coronary disease explaining the left ventricular contraction abnormality was confirmed. In-hospital cardiac complications were defined as cardiogenic shock, pulmonary edema, sustained ventricular tachycardia or ventricular fibrillation, complete atrioventricular block, thromboembolism, cardiac rupture, and cardiac death. Multivariate logistic regression analysis was performed to predict in-hospital cardiac complications. Results: In-hospital cardiac complications were observed in 61 patients (40%). There were 25 patients with cardiogenic shock (16%) and 44 patients with pulmonary edema (29%). Sustained ventricular tachycardia or ventricular fibrillation, complete atrioventricular block, and thromboembolism were noted in 10 (7%), 4 (3%) and 4 patients (3%), respectively. Four cardiac deaths (3%) were observed. Of these, one patient died of cardiac rupture. Multivariate logistic regression analysis identified systolic blood pressure (odds ratio=0.97, 95% CI=0.95-0.98, p &lt;0.01), LV ejection fraction (odds ratio=0.95, 95% CI=0.91-0.98, p &lt;0.01), and β-blocker use before admission (odds ratio=8.72, 95%CI=1.00-194.2, p =0.049) as independent predictors of cardiac complications during hospitalization. Conclusion: Low systolic blood pressure and low LV ejection fraction are independent predictors of in-hospital cardiac complications in patients with TC. Furthermore, β-blocker use before admission is associated with worse outcomes during hospitalization.
P2.03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience
Authors: K. Perdrizet, T. Stockley, J. Law, M. Shabir, L. Le, M. Tsao, S. Kamel-Reid, T. Zhang, M. Sawczak, D. Hwang, P. Pal, G. Liu, P. Bradbury, F. Shepherd, A. Sacher, N. Leighl
Journal: Journal of Thoracic Oncology (2018)
P1.03-03 Molecular Characteristics of Chinese Patients with TSC2-Mutated Non-Small-Cell Lung Cancer: A Retrospective Study
Authors: Z. Huang, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
P2.01-08 Conversion Surgery for Locally Advanced Lung Adenocarcinoma Harboring Driver Gene Mutation After TKI Followed by Cytotoxic Agent
Authors: M. Aoki, T. Umehara, G. Kamimura, T. Tokunaga, T. Nagata, A. Takeda, N. Yokomakura, K. Kariatsumari, M. Yanagi, M. Sato
Journal: Journal of Thoracic Oncology (2018)
Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1
Authors: L.-T. Chen, T.M. Macarulla, J. Blanc, B. Mirakhur, F.A. de Jong, B. Belanger, T. Bekaii-Saab, J. Siveke
Journal: Annals of Oncology (2018)
High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4
Authors: B.W. Higgs, C.A. Morehouse, P.Z. Brohawn, S. Sridhar, R. Raja, G. Gao, J. Englert, K. Ranade
Journal: Annals of Oncology (2018)
P1.12-15 Distinctive Clinical Characteristics of SCLC in Never-Smokers
Authors: I. Mian, S. Nichols, A. Abernethy, K. Carson, K. Maignon, A. Torres, J. Snider, G. Frampton, G. Li, E. Sharon, E. Szabo, A. Thomas
Journal: Journal of Thoracic Oncology (2018)
Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results
Authors: E. Esin, O.B. Cakmak Oksuzoglu, A. Bilici, I. Cicin, S. Aksoy, A. Alacacioglu, M.A. Kaplan, D. Cabuk, A.T. Sumbul, S. Paydas, A. Sakin, Ö Er, T. Korkmaz, N. Yildirim, M. Artac, H. Harputluoglu, P.F. Yumuk, G. Basaran, B. Oyan Uluc, U. Demirci
Journal: Annals of Oncology (2018)
Safe switch of treatment from the reference product to RGB-02, a proposed biosimilar pegfilgrastim: Analysis of the results of three clinical trials
Authors: A. Illes, L. Perjesi, K. Horvat-Karajz, N. Jeszenoi, I. Aradi, N.K. Singh, S.J. Mair, Z. Kahan
Journal: Annals of Oncology (2018)
P1.14-19 Hemagglutinating Virus of Japan Envelope (HVJ-E: Inactivated Viral Nanoparticles) Against Chemotherapy-Resistant Pleural Mesothelioma
Authors: K. Sakura, C. Lee, Y. Kaneda, T. Nakano, S. Atagi, Y. Kadota, K. Kuribayashi, M. Kuroyama, T. Kijima, A. Kumanogoh, M. Okumura
Journal: Journal of Thoracic Oncology (2018)
Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)
Authors: R.S. Herbst, E.B. Garon, D.-W. Kim, B. Chul Cho, J.L. Pérez Gracia, J.-Y. Han, C. Dubos Arvis, M. Majem, M. Forster, I. Monnet, S. Novello, Z. Szalai, M.A. Gubens, W.-C. Su, G.L. Ceresoli, A. Samkari, E. Jensen, G.M. Lubiniecki, P. Baas
Journal: Annals of Oncology (2018)
Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)
Authors: I. Hwang, J. Kang, C. Yoo, J.H. Jeong, K.-P. Kim, H.-M. Chang, B.-Y. Ryoo
Journal: Annals of Oncology (2018)
MA09.10 Molecular Profiling and PD-L1 Status in 900 Cases of Surgically Resected Non-Small Cell Lung Cancer with Clinical and Pathological Correlation
Authors: Z. Xu, M. Castonguay, W. Greer, A. Alwithenani, D. Bethune, A. Drucker, G. Flowerdew, M. Forsythe, D. French, H. Henteleff, M. Johnston, M. Macneil, W. Morzycki, M. Plourde, S. Snow, A. Surette
Journal: Journal of Thoracic Oncology (2018)
P1.04-30 A Potential Effect of Diabetes Mellitus and Metformin Use on Efficacy of Immune Checkpoint Inhibitors (ICI)
Authors: O. Jacobi, Y. Landman, D. Reinhorn, O. Icht, E. Dudnik, O. Rotem, V. Neiman, M. Sarfaty, I. Finkel, D. Hendler, N. Peled, A. Zer
Journal: Journal of Thoracic Oncology (2018)
Resistance to anti-PD-1 therapy is associated with the retention of CXCR3+ CD4+ CD8- T cells in blood
Authors: X. Han, T. Tan, J. Sun, X. Chen, X. Cai, P. Lin, Y. Tan, B. Wang, Y. Wang, J. Wang, Z. Yu, X. Wu, Q. Xu, Y. Gu
Journal: Annals of Oncology (2018)
Androgen receptor expression in breast cancer brain metastases
Authors: E.S. Bergen, A.S.S. Berghoff, U. Rajky, M. Rudas, Z. Bago-Horvath, R. Exner, K. Dieckmann, G. Widhalm, M.I. Gnant, C.C. Zielinski, G.G. Steger, M. Preusser, R. Bartsch
Journal: Annals of Oncology (2018)
Exposure to 3‐methyl‐4‐nitrophenol facilitates development of intestinal allergy
Authors: Jiang‐Qi Liu, Shan‐Shan Li, Li‐Hua Mo, Dian Yu, Xiao‐Rui Geng, Jing‐Yi Hong, Hai‐Qiong Yu, Li‐Teng Yang, Rui‐Di Xie, Zhi‐Qiang Liu, Zhi‐Gang Liu, Ping‐Chang Yang
Journal: Allergy (2018)
Circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) from HIV-infected patients is associated to shorter overall survival (OS): Results from phase II trial (IFCT-1001 CHIVA)
Authors: M. Wislez, H. Blons, C. Domblides, F. Barlesi, J. Mazieres, I. Monnet, L. Kiakouama Maleka, X. Quantin, L. Taillade, H. Lena, P. Fraisse, H. Janicot, C. Audigier Valette, E. Amour, A. Langlais, N. Rabbe, J. Cadranel, P. Laurent puig, A. Lavolé
Journal: Annals of Oncology (2018)
P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTIC
Authors: M. Garassino, B.C. Cho, J. Kim, J. Mazieres, J. Vansteenkiste, H. Lena, J. Corral, J. Gray, J. Powderly, C. Chouaid, P. Bidoli, P. Wheatley-Price, K. Park, R. Soo, Y. Huang, C. Wadsworth, P. Dennis, N. Rizvi
Journal: Journal of Thoracic Oncology (2018)
P1.01-39 Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study
Authors: M. Huang, Y. Tian, M. He, L. Ren, Y. Gong, F. Peng, Y. Wang, Z. Ding, J. Wang, J. Zhu, Y. Xu, Y. Liu, L. Li, Y. Lu
Journal: Journal of Thoracic Oncology (2018)
The Vedic View of Vitiligo
Authors: Paras Patel, Sanjna Sanghvi, Parth Patel
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
P1.04-36 Tislelizumab Combined With Chemotherapy as First-Line Treatment in Chinese Patients With Advanced Lung Cancer
Authors: J. Zhao, Z. Wang, Z. Ma, J. Cui, Y. Shu, Z. Liu, Y. Cheng, S. Leaw, J. Li, F. Xia, J. Wang
Journal: Journal of Thoracic Oncology (2018)
P3.04-24 EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC with PD-L1 ≥50%, a Phase 3 Study
Authors: N. Rizvi, S. Lee, P. Curtis, W. Caldwell, B. Gao, P. Rietschel
Journal: Journal of Thoracic Oncology (2018)
P1.09-02 PD-L1 Expression Pattern in Large Cell Neuroendocrine Carcinoma of the Lung: The GFPC 03-2017 "EPNEC" Study
Authors: D. Arpin, M. Charpentier, M. Bernardi, A. Boni, E. Watkin, I. Goubin-Versini, R. Lamy, N. Piton, L. Gérinière, F. Forest, R. Gervais, I. Monnet, A. Madroszyk, F. Guisier, C. Serrand, C. Locher, C. Decroisette, J.B. Auliac, T. Jeanfaivre, H. Doubre, G. Francois, D. Damotte
Journal: Journal of Thoracic Oncology (2018)
P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC
Authors: L. Paz-Ares, L. Urban, C. Audigier-Valette, F. Grossi, K. Jao, J. Aucoin, H. Linardou, E. Vladimirovna Poddubskaya, J. Fischer, A. Curioni Fontecedro, H. Groen, K. Vermaelen, M. Bourhaba, D. Kowalski, R. Pillai, D. Spigel, S. Ahmed, W. Hu, D. Vickery, J. Fiore, N. Ready
Journal: Journal of Thoracic Oncology (2018)
P1.15-07 Geriatric Oncology - Lung Cancer in Elderly Patients and Palliative Treatment: Prospective Analysis of A. C. Camargo Cancer Center
Authors: M.D. Donadio, A.C.D. Oliveira, L. Leite, M.V. Barbosa, T. Felismino, M. Corassa, V.C.D. Lima, V.H.D. Jesus, A.L. Dettino
Journal: Journal of Thoracic Oncology (2018)
Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study
Authors: N.-J. Chiang, K.K. Tsai, J.-S. Chen, S.-H. Yang, H.-H. Hsiao, Y.-S. Shan, L.-T. Chen
Journal: Annals of Oncology (2018)
Elevated 70kDa heat shock protein (hsp70) and autophagy levels in peripheral blood mononuclear cells (PBMCs) in women with a malignant breast mass
Authors: A.I. Athanasiou, T. Orfanelli, D. Lapolla, E. Andreopoulou, T.A. Moo, J. Marti, T. Cigler, A.M. Bongiovanni, S.S. Witkin
Journal: Annals of Oncology (2018)
Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: Analysis of the MONARCH trials
Authors: H.S. Rugo, S.M. Tolaney, J. Huober, M. Toi, V. André, S. Barriga, T. Forrester, G.W. Sledge, M.P. Goetz
Journal: Annals of Oncology (2018)
A phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01)
Authors: K.-W. Lee, C.H. Maeng, T.-Y. Kim, D.Y. Zang, Y.H. Kim, I.G. Hwang, S.C. Oh, J.S. Chung, H.S. Song, J.W. Kim, S.J. Jeong, J.Y. Cho
Journal: Annals of Oncology (2018)
PL02.01 Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC
Authors: S. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, T. Kurata, A. Chiappori, K.H. Lee, M. De Wit, B.C. Cho, M. Bourhaba, X. Quantin, T. Tokito, T. Mekhail, D. Planchard, Y. Kim, C. Karapetis, S. Hiret, G. Ostoros, K. Kubota, J. Gray, L. Paz-Ares, J. De Castro Carpeño, C. Faivre-Finn, M. Reck, J. Vansteenkiste, D. Spigel, C. Wadsworth, M. Taboada, P. Dennis, M. Özgüroğlu
Journal: Journal of Thoracic Oncology (2018)
A systematic review and meta- analysis of randomized controlled trials to evaluate the risk of gastrointestinal and hepatic toxicities in patients with recurrent ovarian cancer treated with poly adenosine diphosphate ribose polymerase inhibitors maintenance
Authors: K.Z. Thein, A. Sultan, M.H. Zaw, M.M. Han, A.M. Hein, H.H. Aung, S. Awasthi, C. Jones, F. Hardwicke, N. D'Cunha
Journal: Annals of Oncology (2018)
OA13.06 Final Report of a Prospective Randomized Study on Thoracic Radiotherapy Target Volumes with Radiation Dosimetric and Pathologic Analyses
Authors: X. Hu, Y. Bao, Y. Xu, H. Zhu, J. Liu, L. Zhang, X. Yu, Y. Fan, Y. Zhang, W. Sun, W. Mao, M. Chen
Journal: Journal of Thoracic Oncology (2018)
Second-line treatment of bevacizumab plus lomustine versus bevacizumab plus irinotecan in patients with recurrent glioblastoma
Authors: J. Simões, N.T. Tavares, C. Borges, S. Meireles, C. Fernandes, A. Costa, C. Caeiro, M. Damasceno
Journal: Annals of Oncology (2018)

Background: Evidence for second-line treatment of recurrent glioblastoma (rGBM) is scarce and no standard of care is established. A Dutch phase II trial (BELOB) reported promising results with bevacizumab plus lomustine with improved overall survival (OS) and progression free survival (PFS). Therefore, a phase III trial (BELOREC) described maintenance of a PFS improvement; however, OS was not improved. Despite the negative trials, bevacizumab combined with chemotherapy is widely used in rGBM. Methods: Retrospective analysis of adult patients with a first recurrence of a GBM (WHO grade 4) after temozolomide chemoradiotherapy, in the period between 2007 and 2017, at our institution. We selected patients treated with bevacizumab 10 mg/kg every 2 weeks and irinotecan 125 mg/m2 every 2 weeks (BVZ+IRI) or with lomustine 90 mg/m2 every 6 weeks (BVZ+LOM). Survival analysis was performed using the Kaplan-Meier method and prognostic factors assessed by univariate analysis and by the Cox regression model. Results: Of the 154 patients included, the median age was 57 years (19-77) and 64.3% (n = 99) were men. Almost 90% were ECOG-PS 0-1 and the median treatment time was 3 months (0-29). About 70% (n = 108) of the patients were treated with BVZ+IRI and almost 30% (n = 46) with BVZ+LOM. 9-months OS was 37.6% in the BVZ+IRI group, with a median of 7 months (95% CI 5.92-8.08), and 57.3% in the BVZ+LOM group, with a median of 9 months (95% CI 4.55-13.45). For 6-months PFS, it was 35.9% in the BVZ+IRI group, with a median of 4 months (95% CI 3.13-4.87), and 40.6% in the BVZ+LOM group, with a median of 5 months (95% CI 4.29-5.71). In the univariate analysis, BVZ+LOM (p = 0.04), corticotherapy doses response (p = 0.03) and proteinuria (p = 0.04) were prognostic factors for OS. BVZ+LOM (HR 0.49; IC 95% 0.25-0.94; p = 0.03) and corticotherapy doses response (HR 0.52; IC 95% 0.28-0.98; p = 0.04) had a positive impact on OS in multivariate analysis. The most frequent toxicities were trombocitopenia (34.3% in BVZ+IRI and 43.5% in BVZ+LOM; p = 0.28), neutropenia (28.7% and 21.7%; p = 0.37) and leucopenia (23.1% and 17.4%; p = 0.43). Conclusions: According to our data, and despite the samples size difference, BVZ+LOM has a positive prognostic impact in OS comparing to BVZ+IRI. Legal entity responsible for the study: Joana Simões. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer
Authors: M. Nakamura, A. Takashima, T. Denda, M. Gamoh, I. Iwanaga, Y. Komatsu, M. Takahashi, H. Ohori, T. Sekikawa, M. Tsuda, Y. Kobayashi, Y. Miyamoto, M. Kotake, C. Ishioka, K. Shimada, A. Sato, S. Yuki, S. Morita, S. Takahashi, T. Yamaguchi
Journal: Annals of Oncology (2018)
MA04.06 PD-1 Blockade Promotes Hyperprogressive Disease in NSCLC Through Macrophages Activation via Antibody-Fc/FcR Interaction
Authors: G. Sozzi, M. Sommariva, M. Moro, C. Proto, D. Signorelli, M. Ganzinelli, S. Sangaletti, M. Boeri, G. Lo Russo, S. Ferro, E. Tassi, V. Huber, L. Sfondrini, M. Milione, C. Tripodo, M. Colombo, A. Anichini, A. Balsari, L. Rivoltini, M. Garassino
Journal: Journal of Thoracic Oncology (2018)
Somatic-stem transition of tumor cells is a key link in the metastasis
Authors: N.V. Litviakov, M.K. Ibragimova, E.M. Slonimskaya, E.G. Skurikhin, M.M. Tsyganov, O.V. Pershina, I.V. Deriusheva, P.V. Kazantseva
Journal: Annals of Oncology (2018)
P2.01-51 Study of CD26/DPP4 Expression in a Large Series of Non-Small Cell Lung Cancer Patients
Authors: J. Jang, S. Hillinger, M. Haberecker, A. Curioni Fontecedro, F. Janker, I. Gil-Bazo, I. Hwang, K. Kwon, W. Weder, A. Soltermann, W. Jungraithmayr
Journal: Journal of Thoracic Oncology (2018)
OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy
Authors: M. Hellmann, P. Jänne, M. Opyrchal, N. Hafez, L. Raez, D. Gabrilovich, F. Wang, P. Ordentlich, S. Brouwer, S. Sankoh, E. Schmidt, M. Meyers, S. Ramalingam
Journal: Journal of Thoracic Oncology (2018)
P2.11-22 Use of Electronic Medical Records for Tobacco Use and Lung Cancer Screening Documentation in a Large Urban Academic Medicine Practice
Authors: G. Suero-Abreu, K. Sampson, J. Wang, A. Douglas, A. Karatasakis, A. Perez, N. Duma, M. Gonzalez Velez, M. Feurdean, T. Proverbs-Singh, M. Gutierrez
Journal: Journal of Thoracic Oncology (2018)
FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)
Authors: A. Ulusakarya, W. Karray, J. Abdou, A. Karaboué, M. Haydar, S. Krimi, Y. Gumus, W. Almohamad, E. Goldschmidt, P. Biondani, J.F. Morère
Journal: Annals of Oncology (2018)
Functional Nanoparticles: Biological Stimulus‐Driven Assembly/Disassembly of Functional Nanoparticles for Targeted Delivery, Controlled Activation, and Bioelimination (Adv. Healthcare Mater. 20/2018)
Authors: Xi Hu, Fangyuan Li, Shuying Wang, Fan Xia, Daishun Ling
Journal: Advanced Healthcare Materials (2018)

The interlocking of the black and white images in the Taiji diagram shows the on/off stage of functional nanosystems. Moreover, single fish mean a nanoparticle as a small unit, while a school of fish stands for the assembly of nanoparticles. This work is highlighted in article 1800359 by Fangyuan Li, Daishun Ling, and co-workers, where the controllable assembly-disassembly mutual switch or structural composition/conformation change can amplify the imaging signal, enhance the therapeutic effect, as well as achieve the desirable bioelimination in the living body.
Comparison of 3-weekly cisplatin versus 3-weekly carboplatin in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) receiving concurrent chemoradiotherapy (CCRT): A multicenter retrospective study
Authors: A. Dechaphunkul, P. Danchaivijitr, R. Jiratrachu, T. Dechaphunkul, C. Sookthon, C. Jiarpinitnun, C. Paoin, J. Setakornnukul, S. Niyomnaitham, B. Suktitipat, P. Pattaranutaporn, N. Ngamphaiboon
Journal: Annals of Oncology (2018)
Abstract 20818: Liver Fat Content, NAFLD, and Ischemic Heart Disease: Mendelian Randomization and Meta-Analysis of 279,013 Individuals
Authors: Bo Lauridsen, Stefan Stender, Thomas Kristensen, Klaus Kofoed, Lars Køber, Børge Nordestgaard, Anne Tybjærg-Hansen
Journal: Circulation (2017)

Background: In observational epidemiological studies, non-alcoholic fatty liver disease(NAFLD) is associated with high risk of ischemic heart disease(IHD). Hypothesis: To test the hypothesis that a high liver fat content or a diagnosis of NAFLD is a causal risk factor for IHD. Methods: In a cohort study of the Danish general population(N=94,708/IHD=10,897), we first tested whether high liver fat content or a diagnosis of NAFLD was associated observationally with IHD. Subsequently, using Mendelian randomization, we tested whether a genetic variant in PNPLA3 I148M(rs738409), a strong and specific genetic cause of high liver fat content and NAFLD, was causally associated with risk of IHD. Results: Risk of IHD increased stepwise with increasing liver fat content(in quartiles) up to an odds ratio(OR) of 2.41(1.28-4.51)(P-trend=0.004). The corresponding OR for IHD in individuals with versus without NAFLD was 1.65(1.34-2.04)(P=3x10-6). PNPLA3 I148M genotype was associated with a stepwise increase in liver fat co...
Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial
Authors: David C. Currow, Magnus Ekström, Sandra Louw, Julie Hill, Belinda Fazekas, Katherine Clark, Patricia M. Davidson, Christine McDonald, Dimitar Sajkov, Nikki McCaffrey, Matthew Doogue, Amy P. Abernethy, Meera Agar
Journal: European Respiratory Journal (2018)

Does sertraline provide symptomatic relief for chronic breathlessness in people with advanced disease whose underlying cause(s) are optimally treated? 223 participants with chronic breathlessness (modified Medical Research Council breathlessness scale ≥2) who had optimal treatment of underlying cause(s) were randomised 1:1 to sertraline 25–100 mg (titrated upwards over 9 days) or placebo for 4 weeks. The primary outcome was the proportion who had an improvement in intensity of current breathlessness &gt;15% from baseline on a 100-mm visual analogue scale. The proportion of people responding to sertraline was similar to placebo for current breathlessness on days 26–28 (OR 1.00, 95% CI 0.71–1.40) and for other measures of breathlessness. Quality of life in the sertraline arm had a higher likelihood of improving than in the placebo arm over the 4 weeks (OR 0.21, 95% CI 0.01–0.41; p=0.044). No differences in performance status, anxiety and depression, or survival were observed. Adverse event rates were similar between arms. Sertraline does not appear to provide any benefit over placebo in the symptomatic relief of chronic breathlessness in this patient population.
A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study)
Authors: A. Shimomura, K. Tamura, T. Mizutani, T. Shibata, F. Hara, T. Fujisawa, N. Niikura, T. Hojo, C. Kambayashi, S. Saji, N. Masuda, M. Sawaki, N. Yamamoto, F. Nagashima, T. Shien, H. Iwata
Journal: Annals of Oncology (2018)